Clinical trial
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic…
NCT00494897 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00494897 |
|---|---|
| Title | PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia |
| Official title | PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acute Lymphoblastic Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin, Mercaptopurine, Prednisone, Vincristine, Methotrexate, Intrathecally treatment |
| Enrollment | 374 |
| Start date | Jun 1, 1996 |
| Primary completion | May 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jul 2, 2007 |
| Last update posted | May 19, 2009 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: